Feature|Articles|November 7, 2026

8 takeaways from the MHE and Drug Topics post-midterms webinar

Author(s)Peter Wehrwein, Managing Editor

Expect Democrats to flex their oversight powers even if President Donald Trump’s veto power blocks their efforts to reverse Medicaid cuts or restore enhanced ACA subsidies. The administration’s most-favored-nation policies and HHS Secretary Kennedy will probably be in the hot seat.

Many thanks to the panelists for Managed Healthcare Executive and Drug Topics webinar on Thursday about healthcare policy and politics after the midterms:Theresa Carnegie, J.D., a healthcare and pharmaceutical chain attorney at Mintz Levin; Alicia Silver, M.P.P., vice president of market access policy strategy at ADVI Health; and Ron Lanton, J.D., a senior partner at Lanton, Lanton and Sosa. It was a lively, insightful conversation in the wake of election results on Tuesday that took most everybody by surprise. A recording of the webinar will be posted here soon. Here are five takeaways from the webinar.

Related to this article

November 6th, 2026

Medicare changes are here to stay. 3 ways health plans can support members through them

Health plans should be using data, digital tools and human support to identify potential disruptions early, and whether a member is changing plans or managing a new health condition, the experience should feel guided rather than overwhelming.

November 6th, 2026

Cigna’s third-quarter earnings show a drop in income from its pharmacy benefit business

Pretax adjusted income from operations from Express Scripts, Cigna's pharmacy benefit manager, fell by 21.5% compared with the third quarter of 2025, while income from operations of its specialty drug business jumped by 15%.

November 6th, 2026

'Bad data in, means bad data out'—pharmacists on the limits of AI in managed care

Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.

November 6th, 2026

FDA approves Weltruza, first once-monthly subcutaneous olanzapine injection for schizophrenia

Teva’s Weltruza delivers olanzapine monthly under the skin, with no loading doses, oral supplementation or post-injection monitoring required.

November 6th, 2026

Christopher Stanley, M.D., MBA, on culture change and implementing value-based care

Value-based care has scored some cost-saving successes, says Christopher Stanley, M.D., MBA, president of Henry Ford Health's Populance. Health systems that build their own value-based care strategy, rather than adopting particular models one by one, will be in the best position to succeed, he says.

November 6th, 2026

On Populance's pivot to internal customers, some early wins and the current state of value-based care | A conversation with Christopher Stanley, M.D.. MBA

The second half of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.

November 6th, 2026

On becoming a pediatrician, lessons learned in the Army and the Sutter way of doing thing | A conversation with Christopher Stanley, M.D., MBA

The first part of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.

November 6th, 2026

Christopher Stanley, M.D., MBA, on the early population health wins of Henry Ford Health's Populance

Unifying care management doubled patient outreach with the same staff, and virtual physical therapy is cutting costs, says Populance's Christopher Stanley, M.D.